Esrar Kullanımı Sırasında Başlayan ve N, N- Dimetiltriptamin (Dmt) Kullanımı ile Psikotik Özellikler Eklenen Duygudurum Bozukluğu: Bir Olgu Sunumu / A Mood Disorder Episode with an Onset Under Chronic Cannabis Consumption, and Accompanied With Psychotic Features Immediately After N,N-Dimethyltryptamine (Dmt) Use: A Case Report
Gökhan Umut, İlker Küçükparlak, Güliz Özgen, Ahmet Türkcan
Dusunen Adam: The Journal of Psychiatry and Neurological Sciences April 21, 2011 DOI: 10.5350/dajpn2011240312 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Case report Peer reviewed |
|---|---|
| Sample size | 1 |
| Population | A person with chronic cannabis use and a hypomanic episode who consumed DMT |
| Topics | 5-MeO-DMT Cannabis DMT |
| Citations | 2 |
| Key findings | Immediately after DMT use, a hypomanic episode in a chronic cannabis user developed psychotic features. |
Abstract
A mood disorder episode with an onset under chronic cannabis consumption and accompanied with psychotic features immediately after N,N-Dimethyltryptamine (DMT) use: case report N,N-dimethyltryptamine (DMT) is a serotonin agonist hallucinogen, similar to lysergic acid diethylamide (LSD).Synthetic production of DMT as well as extraction from several plants of South American flora is possible.DMT might induce feelings of unity with the cosmos and experiences of eternity, and it is a natural content of a traditional South American beverage -ayahuasca-which is consumed at shamanistic rituals.There is not any data on the abuse of DMT in Turkey to date.We here present a case characterised by sudden and dramatic changes in the clinical features of a hypomanic episode induced after three years of cannabis use, immediately after consuming DMT due to the addition of psychotic features.Key words: N,N
Comparable studies
Other case reports and case series on 5-MeO-DMT, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation. 25-year-old white male | 2005 | Case study | n = 1 |
| Combined intoxication with methylone and 5-MeO-MIPT 27-year-old male patient | 2006 | Case report | n = 1 |
| Sudden death associated with intravenous injection of toad extract. A 24-year-old male | 2009 | Case study | n = 1 |
| 5-Meo-DALT-induced Cyclic Myoclonus (P3.013) A 29-year-old man with history of heroin and marijuana abuse | 2015 | Case report | n = 1 |
| A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder. 31-year-old male military veteran with moderate alcohol use disorder | 2018 | Case study | n = 1 |
Citations in the library
Cites 6
- Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. Pharmacology & Therapeutics May 1, 2004
- Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids Addiction December 20, 2006
- Psychological Effects of (S)-Ketamine and N,N-Dimethyltryptamine (DMT): A Double-Blind, Cross-Over Study in Healthy Volunteers Pharmacopsychiatry November 1, 2005
- Altered consciousness states and endogenous psychoses: a common molecular pathway? Schizophrenia Research December 19, 1997
- Pharmacological modulation of the neural basis underlying inhibition of return (IOR) in the human 5-HT2A agonist and NMDA antagonist model of psychosis. Psychopharmacology November 2008
and 1 more in the library